Feiyu Wang

Tianjin, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

A phase III clinical trial on the immunogenicity of a tetanus vaccine, adsorbed in individuals aged 18 years and above in China.

A phase III clinical trial on the immunogenicity of a tetanus vaccine, adsorbed in individuals aged 18 years and above in China.

Journal: Frontiers in immunology
Published: June 05, 2026

Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants.

Immunogenicity and safety of primary three-dose series with diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed in 3 months infants.

Journal: Frontiers in immunology
Published: May 07, 2026

Safety and immunogenicity of diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed after three-dose priming in 2 months age infants: a randomized, blinded, controlled phase III clinical trial in China.

Safety and immunogenicity of diphtheria, tetanus and pertussis (acellular, three components) combined vaccine, adsorbed after three-dose priming in 2 months age infants: a randomized, blinded, controlled phase III clinical trial in China.

Journal: Emerging microbes & infections
Published: January 30, 2026

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in 12-23-Month Children: A Double-Blind, Randomized, Phase III Trial in China.

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in 12-23-Month Children: A Double-Blind, Randomized, Phase III Trial in China.

Journal: Vaccines
Published: October 28, 2025

Preliminarily evaluation the safety and immunogenicity of tetanus, reduced diphtheria and acellular pertussis (five components) combined vaccine, adsorbed (Tdcp) in participants aged 6 years and above: a blinded and randomised, and controlled phase I clinical trial.

Preliminarily evaluation the safety and immunogenicity of tetanus, reduced diphtheria and acellular pertussis (five components) combined vaccine, adsorbed (Tdcp) in participants aged 6 years and above: a blinded and randomised, and controlled phase I clinical trial.

Journal: Frontiers in immunology
Published: April 23, 2025

Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials.

Pooled Analysis of the Effect of Pre-Existing Ad5 Neutralizing Antibodies on the Immunogenicity of Adenovirus Type 5 Vector-Based COVID-19 Vaccine from Eight Clinical Trials.

Journal: Vaccines
Published: February 24, 2025

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial.

The Safety and Immunogenicity of a 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) in Infants: A Double-Blind, Randomized, Phase III Trial.

Journal: Vaccines
Published: October 31, 2024

Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.

Immune responses and transcription landscape of adults with the third dose of homologous and heterologous booster vaccines of COVID-19.

Journal: Frontiers in immunology
Published: July 08, 2024

Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18-49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study.

Preliminary Evaluation of the Safety and Immunogenicity of a Novel Protein-Based Pneumococcal Vaccine in Healthy Adults Aged 18-49: A Phase Ia Randomized, Double Blind, Placebo-Controlled Clinical Study.

Journal: Vaccines
Published: June 13, 2024
Showing 1-9 of 9

Last Updated: 09/26/2026